Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Down 51.5% in February

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 4,900 shares, a decrease of 51.5% from the February 13th total of 10,100 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 145,500 shares, the days-to-cover ratio is presently 0.0 days.

Emmaus Life Sciences Stock Performance

Shares of OTCMKTS EMMA traded down $0.00 during mid-day trading on Friday, reaching $0.03. 20,578 shares of the company’s stock were exchanged, compared to its average volume of 53,421. The firm has a market capitalization of $1.75 million, a price-to-earnings ratio of -0.30 and a beta of 6.47. Emmaus Life Sciences has a 52-week low of $0.00 and a 52-week high of $0.13. The company’s 50-day moving average is $0.02 and its 200-day moving average is $0.02.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.